Trinity Biotech (NASDAQ:TRIB) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a report issued on Friday. The firm issued a sell rating on the stock.

Trinity Biotech Price Performance

Shares of NASDAQ:TRIB opened at $0.69 on Friday. Trinity Biotech has a 1 year low of $0.63 and a 1 year high of $3.55. The business has a 50 day simple moving average of $0.81 and a two-hundred day simple moving average of $1.19. The firm has a market capitalization of $12.37 million, a PE ratio of -0.30 and a beta of 1.20.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC raised its holdings in shares of Trinity Biotech plc (NASDAQ:TRIB) by 5.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 378,590 shares of the company’s stock after buying an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 78.97% of the company’s stock.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.